Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)

NCT04194775 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.

NCT NCT04194775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04194775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
CStone Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 13, 2019
Completion date
September 30, 2026
Enrollment
534 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma